Among the different phenotypic features identified in ctDNA, the RB-LOH signature16 was found as one of the top signatures associated with survival outcomes in patients with advanced HR+/HER2- breast cancer treated with endocrine therapy in combination with a CDK4/6 inhibitor. This evidence concerns the gene ERBB2 and breast carcinoma.